Jannie Borst

Stem-like PD-1<sup>+</sup>TCF-1<sup>+</sup> CD8<sup>+</sup> T cells result from helpless priming and rely on CD4<sup>+</sup> T-cell help to complete their cytotoxic effector differentiation.

Phagocytosis of necroptotic cells optimizes type 1 conventional dendritic cells for induction of a cytotoxic T-cell response.

Requirements for development of T helper 1 and T follicular helper cells from a common precursor.

CD70 recruitment to the immunological synapse is dependent on CD20 in B cells.

CD4<sup>+</sup> T-cell help delivery to monocyte-derived dendritic cells promotes effector differentiation of helper and cytotoxic T cells.

CD27 costimulation supports metabolic fitness of CD4+ T cells by enhancing de novo nucleotide and protein synthesis.

Histone methyltransferase DOT1L maintains cell state and restricts cytotoxic potential of CD8 T cells.

Histone methyltransferase DOT1L maintains identity and restricts cytotoxic potential of CD8 T cells

Requirements for development of T-helper1 and T-follicular helper cells from a common precursor

Lymph node and tumor-associated PD-L1+ macrophages antagonize dendritic cell vaccines by suppressing CD8+ T cells

Immune suppression by human thymus-derived effector Tregs relies on glucose/lactate-fueled fatty acid synthesis

The importance of type I interferon in orchestrating the cytotoxic T-cell response to cancer.

CD4+ helper T cells endow cDC1 with cancer-impeding functions in the human tumor micro-environment

Multiomics and spatial mapping characterizes human CD8 ⁺ T cell states in cancer

CD4⁺ helper T cells endow cDC1 with cancer-impeding functions in the human tumor micro-environment.

Multiomics and spatial mapping characterizes human CD8⁺ T cell states in cancer.

Trial watch: Dendritic cell (DC)-based immunotherapy for cancer

Trial watch: Dendritic cell (DC)-based immunotherapy for cancer.

TNFR2 Costimulation Differentially Impacts Regulatory and Conventional CD4+ T-Cell Metabolism

TNFR2 Costimulation Differentially Impacts Regulatory and Conventional CD4⁺ T-Cell Metabolism.

Preclinical characterization and clinical translation of pharmacodynamic markers for MK-5890: a human CD27 activating antibody for cancer immunotherapy.

Proteomics reveals unique identities of human TGF-β-induced and thymus-derived CD4⁺ regulatory T cells.

TNFR2 costimulation differentially impacts regulatory and conventional CD4 ⁺ T-cell metabolism

Autotaxin impedes anti-tumor immunity by suppressing chemotaxis and tumor infiltration of CD8⁺ T cells.

Mechanism of action of PD-1 receptor/ligand targeted cancer immunotherapy.

Clinically applicable CD34⁺-derived blood dendritic cell subsets exhibit key subset-specific features and potently boost anti-tumor T and NK cell responses.

Flagellin/TLR5 Stimulate Myeloid Progenitors to Enter Lung Tissue and to Locally Differentiate Into Macrophages.

Immunogenomic, single-cell and spatial dissection of CD8⁺T cell exhaustion reveals critical determinants of cancer immunotherapy

Proteomics reveals unique identities of human TGF-β-induced and thymus-derived CD4 ⁺ regulatory T cells

Changes in Bcl-2 members after ibrutinib or venetoclax uncover functional hierarchy in determining resistance to venetoclax in CLL.